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Background: Orexin A (OXA, hypocretin/hcrt 1) is a newly discovered potential analgesic substance. However,
whether OXA is involved in acupuncture analgesia remains unknown. The present study was designed to
investigate the involvement of spinal OXA in electroacupuncture (EA) analgesia.
Methods: A modified rat model of post-laparotomy pain was adopted and evaluated. Von Frey filaments were
used to measure mechanical allodynia of the hind paw and abdomen. EA at 2/15 Hz or 2/100 Hz was performed
once on the bilateral ST36 and SP6 for 30 min perioperatively. SB-334867, a selective orexin 1 receptor (OX1R)
antagonist with a higher affinity for OXA than OXB, was intrathecally injected to observe its effect on EA analgesia.
Results: OXA at 0.3 nmol and EA at 2/15 Hz produced respective analgesic effects on the model (P<0.05).
Pre-surgical intrathecal administered of SB-334867 30 nmol antagonized OXA analgesia and attenuated the
analgesic effect of EA (P<0.05). However, SB-334867 did not block fentanyl-induced analgesia (P>0.05). In addition,
naloxone, a selective opioid receptor antagonist, failed to antagonize OXA-induced analgesia (P>0.05).
Conclusions: The results of the present study indicate the involvement of OXA in EA analgesia via OX1R in an
opioid-independent way.
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Acupuncture has been used in China since ancient
times to relieve many different types of pain. This ap-
proach has few side effects and is considered to be a
new, effective alternative medicine in Western coun-
tries. However, the mechanism underlying acupuncture
analgesia remains unclear. Although the opioid system
is definitely involved in acupuncture analgesia, nalo-
xone, an opioid receptor antagonist, can only partially
block the analgesic effect of acupuncture [1-4]. Also, in
some studies, naloxone failed to reverse pain thresholds
that had been elevated by acupuncture [5,6]. Studies* Correspondence: gcwu@shmu.edu.cn
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reproduction in any medium, provided the orshow that acupuncture can regulate many types of
neuropeptides besides opioids, i.e. orphanin FQ, chole-
cystokinin, neuropeptide Y [7,8], neurokinin A, and
substance P [8,9], to achieve therapeutic as well as
analgesic effects [10-12]. The above studies showed
that acupuncture analgesia involves some other opioid
independent pathway, and may require the participa-
tion of neuropeptides.
Discovered in 1998, orexin (also known as hypocretin/
hcrt) encodes a hypothalamic neuropeptide precursor
protein that gives rise to two mature neuropeptides,
orexin A (OXA) and orexin B (OXB), by proteolytic pro-
cessing. Hcrt mRNA is mainly expressed in the lateral
and perifornical areas of the posterior hypothalamus
[13,14]. OXA and OXB bind to the orphan G-protein
coupled receptors, orexin-1 receptor (OX1R or HCRTR1),
which is highly selective for OXA, and orexin-2 receptor
(OX2R or HCRTR2), which is nonselective for OXA andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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multiple physiological processes, such as the regulation of
sleep and arousal, feeding behavior, metabolism and noci-
ception. Growing evidence from morphological and be-
havioral studies has demonstrated the anti-nociceptive
role of orexins, particularly OXA. [15-18]. Central nervous
system (CNS) administered (intracranial ventricle or intra-
thecal injection) OXA can suppress mechanical allodynia
and thermal hypersensitivity in multiple pain models
[19-22]. In a rat model of post-operative pain, the anti-
nociceptive effects of OXA were more remarkable than
those of OXB, and the effects of OXA were completely
blocked by adenosine type 1 receptor antagonists [23].
Purinergic P(2X) and glycine receptors are proposed to
be involved in orexin-induced spinal antinociception.
Endocannabinoids and nociceptin/orphanin FQ were
found to interplay with orexins in nociceptive processing
[24]. The antinociceptive effects of intracranial ventricle
injection (i.c.v.) of OXA were greater in histamine H1 re-
ceptor or H2 receptor knockout mice than in wild-type
mice with pain conditions [25]. In addition, orexinergic
projections were identified in periaqueductal gray matter
(PAG), the rostral ventral medulla, the dorsal horn and
dorsal root ganglion [26-28]. The anti-nociceptive effect
of orexins could not be blocked by naloxone at a dose
that blocked dynorphin-induced analgesia [29]. These
studies suggest OXA may be a potential analgesic sub-
stance that acts in an opioid independent manner.
To date, there are few reports on the function of OXA
in acupuncture analgesia. Whether CNS OXA levels
change after surgery or if OXA is involved in electroacu-
puncture (EA) analgesia remains unknown. The present
study was designed to monitor OXA changes post-
surgery and its role in EA analgesia. Using a modified
post-laparotomy pain model, which is more closely
related to clinical use, the present study was intended to
(1) examine the change in OXA levels both in the rat
model of post-laparotomy pain and after EA treatment
of the model; (2) evaluate the modified rat model of
post-laparotomy pain and observe the analgesic effect of
intrathecal injected OXA and EA application on the
model; (3) test the inhibitory effect of the selective
OX1R antagonist, SB-334867, on OXA and EA anal-
gesia; and (4) further verify whether OXA analgesia was
independent of the opioid system in the rat model of
post-laparotomy pain.
Methods
A rat model of post-operative pain [30] was adopted and
modified. Fentanyl, an opioid μ-receptor agonist and a
clinically used analgesic, was selected to evaluate pain
state post-laparotomy. Acupuncture and OXA were sep-
arately employed in the pain model to test whether they
had an analgesic effect. A selective OX1R antagonist,SB-334867, was intrathecally injected to test the possible
involvement of OXA in acupuncture-induced analgesia.
Naloxone was applied before OXA injection to investi-
gate whether it could block OXA analgesia.
Animals
Adult male Sprague–Dawley rats (200–220 g) were pur-
chased from the BK Company (Shanghai, China) and
allowed to acclimate for one week prior to the beginning
of experiments. To minimize possible disturbances, the
animals were housed in a quiet room close to the oper-
ating room with a 12:12-h light/dark cycle. Room
temperature was maintained at 20 ± 2°C. Food pellets
and water were supplied ad libitum. All protocols for
this study were approved by the Animal Care and Use
Committee from Shanghai Medical College, Fudan
University, and the experiments were conducted in ac-
cordance with IASP guidelines for pain research in ani-
mals [31].
Animal husbandry
Animals tend to explore new environments. This may
affect their sensitivity to external stimuli [32]. To
minimize interference and avoid stress-induced analgesia
from the behavioral tests, 4 days prior to the operation,
the animals were each placed out of sight of one another
in the behavioral testing environment, which was an ele-
vated separated chamber (21 cm × 27 cm × 15 cm) with
a mesh floor. The duration of exposure to this area was
successively increased in the next 4 days (1 h for the 1st
day, and 2, 4, 6 h each for the remaining 3 days). On the
day before the operation, when rats were placed on the
mesh floor, they immediately sat still or began grooming,
indicating that they had adjusted to the environment.
Surgery
A rat model of laparotomy pain was established accord-
ing to a previous report [30] and was modified to meet
the aims of the present study. Anesthesia was main-
tained by diethyl ether (5% (v/v)) via a nose cone. The
deepness of anesthesia was measured as follows: 1) the
righting reflex disappeared (the rat could lie on its back);
2) muscular strength class 0 (the limbs of the rat fell
down when lifted and dropped by the surgeon); 3) mus-
cular tension disappeared (the limbs of rat could be
stretched by the surgeon freely). When the deep
anesthesia was achieved, diethyl ether inhalation was
ceased for several minutes and then restarted. Signs of
nociception would appear if the inhalation ceased for a
relatively long time or the diethyl ether was exhausted.
Such signs are muscular contraction, tail flick, righting
reflex and muscular tension. After the preliminary
experiments, we were familiar with the anesthesia
process and able to perform the experiment well.The
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alcohol. A midline incision (changed from 3 cm to 6 cm
long) was made on the abdominal wall, and the viscera
were gently manipulated with the surgeon’s index finger
for 2 min. Next, the abdominal wall was closed with 4–0
sutures. The procedure was completed within 10 min.
Animals in the sham model group were operated as per
the model group, except for the abdominal incision.
Only male Sprague–Dawley rats were selected in the
experiments to avoid possible gender effects on pain
thresholds [33].
EA application
For animals in the groups that received EA stimulation,
EA was applied via two stainless steel needles (0.3 mm
in diameter and 25 mm long) connected with the output
terminals of an EA apparatus, the HANS Acupoint
Nerve Stimulator (LH202H, Beijing, China). The needles
were vertically inserted into bilateral ST36 (Zusanli)
points to a depth of 5 mm and SP6 (Sanyinjiao) points
to a depth of 3 mm. The stimulator was turned on, and
the frequency was adjusted to 2/15 Hz or 2/100 Hz, while
the current was adjusted to 1–3 mA. At this current, slight
shaking of the legs was induced. The time course of EA
application was 30 min, and the operation was conducted
at 10 min for approximately 10 min. For rats in the sham
EA group, needles were inserted into the bilateral ST36
and SP6 points with no current stimulation.
Enzyme-linked immunosorbent assay (ELISA)
Tissue processing for ELISA
Rats in the four groups (normal, model, EA 2/15 Hz and
EA 2/100 Hz) were sacrificed 1 h after surgery or EA.
Samples were collected from the hypothalamus, PAG
and spinal cord (T13-L5). Brain regions were dissected
according to conventional definitions [34]. Peptide ex-
traction was performed according to a previously
described method [35], with slight modifications. Each
sample block was put into a microtube and weighed and
then immersed in 0.5 M acetic acid at a ratio of 1:10 and
boiled for 10 min. Samples were homogenized at 40,000
rpm for 15 s and this process was repeated three times,
each with 15 s interval. Samples were then centrifuged
for 20 min at 5500 rpm. The supernatants were air dried
under a hood overnight, and the dried samples were
subsequently stored at −80°C.
ELISA quantification of orexin A
Dried samples stored at −80°C were used for OXA
measurements, which were quantified using the stand-
ard ELISA kit (EK-003-30) obtained from Phoenix
Pharmaceuticals Inc. (Belmont, CA, USA) according to
the manufacturer instructions. ELISA was chosen to
minimize the usage of radioactive materials and, bothELISA and RIA methods used to quantify orexin have
been evaluated and used [36,37]. Optical densities of
the 96-well microplates were read using an assay reader
(Thermal Spectronic, Madison, WI, USA). After aver-
aging the results of duplicate wells, the peptide value of
each sample was calculated as pg/mg wet tissue.
Drug injections
Fentanyl citrate, an opioid μ-receptor agonist and a
clinically used analgesic, and the control (normal saline
0.2 mL) were intramuscularly (i.m.) injected. SB-334867
(Tocris, UK, dissolved in dimethyl sulfoxide [DMSO]),
naloxone (Sigma, MO, USA, dissolved in normal saline)
or OXA (Tocris, UK, dissolved in normal saline) were
intrathecally injected. Identical volumes of drug vehicle
were administered for comparison with drug-treated
groups in each experiment.
For intrathecal injections, a modified method of the
direct transcutaneous intrathecal injection was used
[38]. After being anesthetized, rats were shaved from
the lower back and sterilized. A cylindrical glass bottle
(60 mm in diameter, high-temperature sterilized) was
put under the rat’s abdomen so that its lower back was
curved. The surgeon’s thumb and middle finger held
the bilateral posterior superior iliac spine, and the index
finger palpated the highest spinous process to locate the
sixth lumbar (L6) spinous process. A 10-μL Microliter
Syringe was inserted from the caudal end, immediately
lateral to the L6 spinous process at a 45° angle to the
vertebral column and was pushed slowly toward the
cranioventral direction. When a sudden lateral tail
movement occurred after penetration of the ligamen-
tum flavum (felt as a pop), the drug or vehicle was
injected slowly for 30 s. The syringe was held for 10 s
more before removal to prevent the outflow of the drug.
In a preliminary study we confirmed the accuracy of
intrathecal injection to L6 with 2% (w/v) Evans blue.
One hour after injection, Evans blue can be seen
throughout the spinal cord, as well as the superior cere-
bellar pool and the midbrain aqueduct, but was difficult
to detect in the lateral ventricle and third ventricle.
Behavioral testing
The von Frey filaments (Stoelting Inc., USA) were used
to identify the severity and duration of mechanical allo-
dynia state in rats according to previously published
literature [39,40]. We introduced the abdominal con-
striction threshold (ACT) in addition to the paw with-
drawal threshold (PWT) to select better assessments
for this model.
ACT and PWT were tested consecutively. Filaments
were applied from underneath the chamber through
openings in the mesh floor to an area 5 mm adjacent to
the abdominal wound line (ACT) or to an area in the
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produced an upward force to induce abdominal con-
striction or paw withdrawal. A preliminary experiment
was conducted to select the proper sequential filaments,
as shown in Table 1.
Each of the sequential von Frey filaments was applied
once for 3 s starting with the minimum and continuing
until an abdominal constriction or foot withdrawal re-
sponse occurred. After a 3-min test-free period, each
filament was again applied once, beginning with the
minimum, until a response was elicited. This was
repeated a third time 3 min later. The lowest force from
the three tests producing a response was considered the
ACT or PWT. The cutoff value, 26.0g, was recorded
even if there was no response to this force. The animals
were tested at baseline, 0.5, 1, 2, 4, 6 and 24 h after sur-
gery. Time 0 was defined as the end of the surgery or
EA application.
The treatment regimes were:
(a) No drug (or EA) treatment:Ta
AC
PWnormal group, model group (rats undergone
surgery) and sham model group (anesthesia only
rats) (n=8 per group).
Post-operative treatment with fentanyl:
To fully evaluate the pain state of the laparotomy
model, rats received a fentanyl injection (5, 10, 20
μg/kg, i.m., n=8 per group) or drug-vehicle (saline
0.2 mL, n=8) immediately after surgery at time 0.
(b) Post-operative treatment with OXA:
To verify whether OXA has an analgesic effect on
the model, rats received intrathecally administered
OXA (0.1, 0.3 and 1.0 nmol, n=8 per group) or
drug-vehicle (normal saline 10 μL, n=6) after
surgery at time 0.
Perioperative treatment with EA:
To explore the EA analgesic effect on the rat model,
EA was applied perioperatively for 30 min, i.e., EA
stimulation (2/15 Hz or 2/100 Hz) begun 10 min
before surgery and ended 10 min after surgery.
During the middle 10 min of EA the surgery was
completed. Thus, when EA was applied in the
experiment, time 0 was defined as the end of EA.
(c) Pre-operative treatment with SB-334867on OXA
analgesia:
To explore whether OXA produces its analgesic
effect via OX1R, the selective OX1R antagonistble 1 Selection of sequential filaments for ACT and PWT be
Before operation
T 8.0 g, 10.0 g, 15.0 g, 26.0 g
T 6.0 g, 8.0 g, 10.0 g, 15.0 g, 26.0 gSB-334867 (30 nmol, n=7) or drug-vehicle (DMSO,
10 μL, n=8) was intrathecally administered prior to
surgery OXA with the minimum effective dose
selected from (c) was intrathecally administered
post-surgery.
Pre- or post-EA treatment with SB-334867:
To examine whether OXA participates in EA
analgesia via OX1R, the selective OX1R antagonist
SB-334867 (30 nmol, n=7-8 per group) or drug
vehicle (DMSO 10 μL) was intrathecally
administered prior to or post-EA-treatment.
(d) Pre-EA treatment with naloxone
To explore whether OXA analgesia was
independent of the opioid system, the opioid
receptor antagonist naloxone 28 nmol or drug
vehicle (saline 10 μl) was intrathecally injected
before surgery OXA, was intrathecally injected after
surgery.
Statistical analysis
Statistical analyses were performed using SPSS 13.0 soft-
ware. Threshold response data were represented as the
mean ± standard error of means (SEM). Between groups,
ACT and PWT data at each time point were analyzed by
a one-way analysis of variance (ANOVA) followed by a
post hoc least significance difference test (LSD). A prob-
ability (p) value of < 0.05 was considered to be statisti-
cally significant.
Results
Changes to OXA levels in the hypothalamus, PAG and
spinal cord following laparotomy and/or EA treatment
The ELISA tests showed that there was a significant de-
crease of OXA peptide levels in the hypothalamus, PAG
and spinal cord in rats after surgery (P<0.05) when com-
pared with the normal group. EA 2/15 Hz reversed the
decrease in OXA levels in the above regions in model
rats (P<0.05), whereas the EA2/100 Hz group showed no
change (P>0.05; Figure 1).
Induction of mechanical allodynia in the rat model of
post-laparotomy pain
In behavioral tests, no statistical difference was found in
the baseline thresholds measured by PWT or ACT
among the tested groups before surgery (P>0.05 by
ANOVA).
No significant difference in mechanical thresholds was
detected between the normal and sham model groupfore and after operation
After operation
0.16 g, 0.4 g, 0.6 g, 1.0 g, 2.0 g, 4.0 g, 6.0 g, 8.0 g, 10.0 g, 15.0 g, 26.0 g
4.0 g, 6.0 g, 8.0 g, 10.0 g, 15.0 g, 26.0 g
Figure 1 OXA levels determined by ELISA in the rat
hypothalamus, PAG and spinal cord in the normal, model,
EA 2/15 Hz and EA 2/100 Hz groups. Data are presented as the
mean ± SEM (n=4 in each group). #P<0.05 versus normal group,
*P<0.05 versus model group. PAG: periaqueductal gray matter.
Figure 2 Mechanical threshold changes (in grams) after surgery with
the mean ± SEM at the indicated time points post-surgery. A, B: abdo
model groups after surgery. C, D: abdominal and paw mechanical changes
the sham model group, #P<0.05 versus the sham model group; *P<0.05, **
duration. Fen: fentanyl, BL: baseline.
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model group displayed significant allodynia to mechan-
ical stimulation in both the hind paw and the abdomen
(P<0.05). PWT significantly decreased at 0.5 h post-
surgery in the model group when compared with the
sham model group (P<0.01). ACT also decreased in the
model group when compared with the sham model
group (P<0.01). These data provide behavioral evidence
for the postoperative pain model.
Relief of mechanical allodynia with fentanyl in the rat
model of post-laparotomy pain
The μ-opioid receptor agonist fentanyl was intramuscu-
larly (i.m.) injected immediately after surgery at 5, 10
and 20 μg/kg. Figure 2C and D show that 10 and 20 μg/
kg of fentanyl dose-dependently increased PWT and
ACT (P<0.05 compared with the saline group). In the
following experiment, ACT was chosen as a mechanicalor without intramuscular injection of fentanyl are presented as
minal and paw mechanical changes among normal, sham model and
among saline, fentanyl 5, 10 and 20 μg/kg groups. ##P<0.01 versus
P<0.01 versus the saline group. Short black lines represent the surgery
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allodynia state and was relatively stable compared with
PWT. These data independently provide evidence that
laparotomy pain can be relieved by analgesia in this
model.
Effect of postoperative OXA injection in the rat model of
post-laparotomy pain
OXA at a concentration of 0.1, 0.3 and 1.0 nmol or sa-
line was intrathecally injected into animals immediately
after surgery. Figure 3A shows that 0.1 nmol OXA did
not have an analgesic effect after surgery, whereas OXA
at 0.3 and 1.0 nmol increased ACT significantly at 0.5 h
compared with the saline group (P<0.05). There was no
statistically significant difference in ACT between the
OXA 0.3 nmol and OXA 1.0 nmol groups. Thus, the 0.3
nmol intrathecally-injected dose was chosen in all subse-
quent experiments.
Effect of perioperative EA application in the rat model of
post-laparotomy pain
Perioperative EA stimulation was applied bilaterally to
the ST36 and SP6 acupoints at 2/15 Hz or 2/100 HzFigure 3 Effect of post-surgical OXA injection (A) and perioperative E
SB-334867 on OXA analgesia (C) and EA analgesia (D). Data are presen
*P<0.05 versus the saline/model/DMSO group. #P<0.05 versus the sham EA
the EA group. Short black line represents the surgery duration. The double
pre-surgical injection of SB-334867; SB-ps: post-surgical injection of SB-3348for 30 min. Surgery was performed during the middle
10 min of EA stimulation. Figure 3B shows that EA at
2/15 Hz significantly increased ACT in the 1st h after
surgery compared with the model group (P<0.05). At
0.5 h, the EA 2/15 Hz group also showed a signifi-
cantly difference in ACT when compared with the
sham EA group (P<0.05). EA at 2/100 Hz produced
significant analgesia as measured by ACT compared
with the model group within 0.5 h (P<0.05). Therefore,
EA stimulation using 2/15 Hz was used for all subse-
quent experiments.Effect of preoperative intrathecal injection of SB-334867
on OXA analgesia in the rat model of post-laparotomy
pain
The OX1R antagonist SB-334867 (30 nmol) was intra-
thecally injected prior to surgery. Figure 3C shows that
there was no significant difference in ACT among the
SB-334867 group, DMSO group and saline group at
0.5 h post-surgery (P>0.05). The SB-334867 30 nmol +
OXA group showed a significant difference when com-
pared with the OXA 0.3 nmol group (P<0.05).A (B) on the rat model of post-laparotomy pain, and effect of
ted as the mean ± SEM at the indicated time points post-surgery.
group, &P<0.05 versus the SB-334867 + OXA group, $P<0.05 versus
-headed arrow represents the EA duration. BL: baseline. SB-pr:
67.
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on EA analgesia in the rat model of post-laparotomy pain
SB-334867 was intrathecally injected into the rat model
in addition to EA application. SB-334867 (30 nmol) had
no obvious effect on the ACT at 0.5 h when compared
with the DMSO group (P>0.05 by one way ANOVA
with LSD test). Pre-surgical treatment with SB-334867
(SB-pr) significantly decreased EA analgesia (P<0.05 by
one way ANOVA with LSD test) (Figure 3D), while
post-surgical administration of SB-334867 (SB-ps) did
not decrease the EA analgesic effect.
Effect of pre-treatment with naloxone on OXA analgesia
and pre-treatment with SB-334867 on fentanyl-induced
analgesia
Naloxone was intrathecally injected at a dose of 28 nmol
pre-surgery followed by an intrathecal injection of OXA
(0.3 nmol) post-surgery. At 0.5 h post-OXA injection,
the OXA 0.3 nmol group and the OXA + Naloxone
group both showed a significant difference in the ACT
when compared with the saline group (P<0.05), whereas
there was no difference between the OXA group and the
OXA + Naloxone group (P>0.05) (Figure 4A).
In another experiment, we intrathecally injected SB-
334867 pre-surgery followed by an intramuscular injec-
tion of fentanyl post-surgery. Results showed there was
no significant difference between the SB-334867 group
and model group, or between the SB-334867 + fentanyl
group and fentanyl group (P>0.05; Figure 4B).
Discussion
The present study showed that after laparotomy, OXA
levels in the hypothalamus, PAG and spinal cord
decreased significantly. Bilateral EA at ST36 and SP6
elevated OXA levels in the above regions. Rats displayed
a local and systematic mechanical allodynia state after
laparotomy. The allodynia could be relieved by fentanylFigure 4 The OXA analgesic effect was not blocked by intrathecal ad
was not blocked by intrathecal administration of SB-334867 (B). Data are p
line represents the surgery duration. BL: baseline; NLX: naloxone; Fen: fentain a dose-dependent manner with a limited time course
of 2 h. OXA at 0.3 nmol and EA at 2/15 Hz both
showed analgesic effects in the rat model. SB-334867
30 nmol blocked OXA-induced analgesia. Pre-surgical,
but not post-surgical, administration of SB-334867
treatment significantly reduced EA analgesia. These
results suggested the involvement of OXA in acupunc-
ture analgesia via OX1R. As we focused on laparotomy
induced pain, indexes such as blood pressure, heart
rate and breath during surgery were not included in
the present study.
Relevance and validity of the model and pain assessment
In this study, we used the mechanical measurement of
ACT in addition to PWT to evaluate the pain state of
the animal. PWT decreased significantly after laparot-
omy; this effect lasted for over 24 h, which is in agree-
ment with previous reports [41,42]. Because paw
withdrawal is a complex reflex that requires spinal and
supraspinal reflexes and includes cerebral involvement,
this reflex can be used to represent the systemic pain
state. The hind paw test is commonly used to evaluate
mechanical pain, including hind paw pain, patellar
osteoarthritis, abdominal incisional pain and tibial can-
cer pain, among others. In abdominal pain following sur-
gery, nerves innervating the hind paw (superficial and
deep branches of the peroneal nerve as well as medial
and lateral plantar nerves) terminate in the lumbar-
sacral segments L6–S2. The surgical site is served by the
lumbar spinal cord segments L1–L4, with some input
from T13. Assessments of the pain state of the abdomen,
not the hind paw, could be more consistent with typical
clinical scenarios. The idea of using the ACT came from
the “abdominal constriction score” or “abdominal with-
drawal response” when assessing visceral inflammatory
pain. We introduced the ACT to evaluate abdominal
mechanical allodynia and compared it with PWT. Asministration of naloxone (A). The fentanyl-induced analgesic effect
resented as the mean ± SEM. *P<0.05 versus saline group. Short black
nyl; SB: SB-334867.
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and PWT was observed in the model group and fentanyl
groups, but ACT remained at a relatively steady level,
whereas PWT gradually increased towards baseline
levels. Thus, the ACT could be more suitable than other
tests in assessing abdominal pain.
Acupoints and EA frequency selection
In the present study, we selected the bilateral acupoints
of ST36 and SP6 to relieve laparotomy pain. In Chinese
medicine, pain is believed to be caused by either Qi flow
stagnation or Qi-blood insufficiency. In the laparotomy
case, abdominal pain is caused by incision, which
induces Qi and blood stagnation. ST36 and ST6 have
been reported to alleviate many kinds of abdominal pain
by regulating and activating Qi and blood movements.
When Qi flows smoothly, the pain is relieved. Some
studies have found that after EA at ST36, high IL-1
Receptor-I mRNA expression of PAG due to peripheral
inflammation was inhibited and the high pain thresh-
old significantly increased [43]. This indicates the anal-
gesia of EA at ST36 may be a consolidation of signals
at the PAG level. In the present study, we have found
that EA at the bilateral ST36 and SP6 increased the
mechanical threshold of rats after laparotomy, as com-
pared with the model group.
EA analgesia is achieved by integration of the wave,
pulse width, frequency and intensity of stimulation on
acupoints. Among these factors, frequency is a key factor
affecting the analgesic effect of EA. We selected 2/15 Hz
and 2/100 Hz for EA administration and compared the
analgesic effects of these two frequencies. Our results
show that 2/15 Hz produced a better analgesic effect in
the rat model. Experimental studies have shown that dif-
ferent frequencies can cause the brain and spinal cord to
release different types of opioid peptides, which may
have different effects [44]. EA stimulation at 2 Hz accel-
erates the release of endorphins in the brain and large
amounts of enkephalin in the spinal cord [45-47], while
15 Hz EA stimulation causes the release of endorphins,
beta-endorphin, endomorphin and dynorphin, and 100
Hz EA stimulation causes the spinal cord to release
dynorphin [10,48-51]. Thus, 2/15 Hz EA stimulation
may accelerate the release of many different endogenous
opioid peptides [52], each of which strengthens the
effect of the others. Therefore, this frequency of EA
can produce a strong analgesic effect.
OXA and EA analgesia
Recent studies show that orexins, especially OXA, may
play an important role in pain modulation. Previous
studies showed that OXA injection into the posterior
hypothalamus of rats reduced the afference of facial A-
and C-fibers to electrical and heat stimulation, whileOXB increased the afferent response to heat stimuli
[53]. In addition, prepro-orexin (PPO) knockout mice
displayed significant hyperalgesia and reduced stress-
induced analgesia compared with wild-type mice, sug-
gesting that pain and stress stimulate the orexin system
to modulate the pain transmission process [54]. Orexin
participates in the nociceptive process both at the spinal
cord and supraspinal cord level and may also be
involved in the descending inhibitory system of pain
regulation [26-28].
The present study showed that intrathecal injection of
OXA can relieve the pain state induced by laparotomy,
and that this effect was antagonized by the selective
OX1R antagonist SB-334867. The OXA analgesia effect
of 0.3 nmol and 1.0 nmol was not dose-dependent. Simi-
lar observations were made by Bingham et al. [21]. This
result may be because OX1R was already saturated for
OXA at the dose of 0.3 nmol. In the present study, pre-
surgery treatment with SB-334867, instead of post-
surgical SB-334867, blocked EA analgesia. We can infer
it is because EA activated OXA release to achieve the
analgesic effect, which was proven by the ELISA. OXA
has a much higher affinity for OX1R than OXB. The
above results strongly indicate the involvement of
orexin, particularly OXA in EA analgesia. However we
can’t completely exclude the possibility that OXB is also
involved. In another experiment, the analgesic efficacy of
intrathecal injection of OXA was superior to OXB in the
paw incision induced pain model [23]. Nevertheless we
can infer from the present results that OXA is a more
potent factor in participating in EA analgesia than OXB.
Because EA mainly achieves its analgesic effect by
stimulating the release of opioid peptides, whether SB-
334867 blocked EA in an opioid-dependent way was also
studied. We conducted experiments using intrathecal
injections of naloxone, which has an extremely high af-
finity for μ-opioid receptors and a lower affinity at κ-
and δ-opioid receptors in the CNS. Therefore, naloxone
mainly antagonizes the analgesic effect of endorphins, as
well as part of the effects of dynorphin and enkephalin.
There is strong evidence that naloxone can block EA an-
algesia; however, inhibition is not complete. Therefore,
we can’t exclude the role of opioids in acupuncture anal-
gesia. Unfortunately, we did not repeat the naloxone +
EA experiment because our study focused on OXA in-
volvement in acupuncture analgesia.
We found that naloxone (28 nmol), at a dose that
blocked dynorphin-induced analgesia, was unable to
block OXA-induced analgesia. This result is in accord-
ance with previous studies [21,29]. Also, the OX1R re-
ceptor antagonist SB-334867, at a dose that blocked EA
analgesia, did not block fentanyl-induced analgesia.
In addition, OXA levels in the hypothalamus, PAG
and spinal cord also decreased significantly after
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are included in the descending inhibitory system. This
result has shown that EA can regulate the descending
inhibitory system to achieve an analgesic effect. We can
only infer that the possible reason for an OXA decrease
in the model group is that the laparotomy is a traumatic
injury to rats and induces a stress response, which
causes exhaustion of OXA in the CNS. OXA is produced
through hydrolysis of its precursor PPO by the proteo-
lytic enzyme during the process of axonal transport [55].
The mechanism why EA increased OXA levels remains
to be explored. One possible mechanism is that EA
stimulation promotes the axon transmission of OXA
and accelerates proteolysis, which in turn increases
OXA production and release [56]. Whether EA initiates
the rapid response of cells to achieve the subsequent
effect remains to be clarified. In the present study, only
2/15 Hz increased OXA levels in the above areas. This
may provide further evidence that different frequencies
of EA stimulate the release of different peptides.
Conclusion
Although orexin A (OXA) is a newly discovered poten-
tial analgesic substance, whether OXA is involved in
acupuncture analgesia remains unknown. In this study
we have shown that EA reversed the OXA decrease in
rats post laparotomy. Intrathecal administered of OX1R
antagonist SB-334867 antagonized OXA analgesia and
attenuated the analgesic effect of EA, but did not block
fentanyl-induced analgesia. In addition, naloxone failed
to antagonize OXA-induced analgesia. The results of the
present study indicate the involvement of OXA in EA
analgesia via OX1R in an opioid-independent way.
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